A Single-Center, Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics Profile of Aom0319 in Healthy White Subjects
Latest Information Update: 29 Nov 2024
At a glance
- Drugs Adamgammadex sodium (Primary)
- Indications Brain injuries
- Focus Adverse reactions
Most Recent Events
- 27 Nov 2024 Status changed from recruiting to completed.
- 23 Nov 2023 Planned End Date changed from 1 Mar 2024 to 1 Jun 2024.
- 26 Oct 2023 Planned number of patients changed from 56 to 32.